SKB575 vs WIN378

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: TSLP · full Asthma pipeline

SKB575

Developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 1 in Asthmabispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT07732023 (registry estimate)

No aligned efficacy figure on record for this race.

WIN378

Developed by Windward Bio and partners

Phase 2/3 in Asthmamonoclonal antibody
Weak signal

NCT05790694 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events" (with 6 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: October 2028 · NCT07120503 (registry estimate)

Reported efficacy

Adverse events (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-AUC0-last (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Tmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Cmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-CL/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Vd/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-T1/2 (Strat of Treatment to end of study (approsimately 160days)): In 50 healthy adults given single doses of 20, 60, 200, 600 or 900 mg (eight on drug and two on placebo at each level), treatment-emergent adverse events were comparable between dose groups and placebo, with no trend for increasing risk with dose escalation. Anti-drug antibody incidence was 5% (2 of 40), no injection site reactions occurred, mean half-life ranged from 55.0 to 65.8 days, and exposure increased in a near dose-proportional manner from 20 to 900 mg.

Result source: NCT05790694

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSKB575WIN378
Severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change—Not reported—Not reported
ACQ-5, change—Not reported—Not reported
OCS dose reduction—Not reported—Not reported

Severe exacerbations, annualised rate

SKB575
—Not reported
WIN378
—Not reported

Trough FEV1, change

SKB575
—Not reported
WIN378
—Not reported

ACQ-5, change

SKB575
—Not reported
WIN378
—Not reported

OCS dose reduction

SKB575
—Not reported
WIN378
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SKB575: no structured comparison results are available for Asthma.

WIN378: no structured comparison results are available for Asthma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SKB575's landscape · WIN378's landscape